Goldstein DOV A MD
SEC-identified person · CIK 1120478 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Bioage Labs, Inc. BIOA | Chief Financial Officer | filed 2024 - 2026 |
| Coya Therapeutics, Inc. COYA | Director | filed 2022 - 2026 |
| Gain Therapeutics, Inc. GANX | Director | filed 2021 - 2025 |
| Ohr Pharmaceutical Inc OHRP | Director | filed 2019 - 2022 |
| R&R Acquisition VI, INC ADMA | Director | filed 2012 - 2020 |
| Esperion Therapeutics, Inc. ESPR | Director | filed 2013 - 2018 |
| Melinta Therapeutics, INC. /NEW/ MLNT | Director | filed 2012 - 2017 |
| Loxo Oncology, Inc. LOXO | Director · CFO and Treasurer | filed 2014 - 2015 |
| Durata Therapeutics, Inc. DRTX | Director | filed 2012 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.